131
Views
3
CrossRef citations to date
0
Altmetric
Case Reports

Ovarian benign clear cell adenofibroma in a patient with premature ovarian failure after 8-year hormone replacement therapy

, &
Pages 216-218 | Received 18 Mar 2012, Accepted 13 Sep 2012, Published online: 16 Nov 2012
 

Abstract

Ovary benign clear cell adenofibroma (CCAF) is extremely rare. Here, we reported a 38-year-old woman with CCAF who was given sequential cyclic hormone replacement therapy for eight years due to premature ovarian failure (POF). At operation, we found adenofibromas in both ovaries and well encapsulated. The cut surface was cystic and solid in appearance, and multilocular cysts embedded in hard stroma. Determination of sex hormone levels in the fluid of cysts of the ovary showed normal level. Clear cell cystadenofibroma proliferation was found in ovarian stroma while atrophy in ovarian cortex. Histological examination revealed that the glands were lined by 1 or 2 layers of hobnail cells with scant to moderate pale or clear cytoplasm. The nuclei were small uniform, and flat to round. Neither primary follicles nor secondary follicles were observed in ovary cortex. Immunohistochemical results showed that EMA and p53 were positive while Calretinin was negative. In this article, we reviewed literatures and analyzed both clinical and pathological features of ovary benign clear cell adenofibromas.

Declaration of Interest: The authors declare no conflicts of interest.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access
  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart
* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.